US Patent

US10646480 — Formulations of pimavanserin

Formulation · Assigned to Acadia Pharmaceuticals Inc · Expires 2038-08-27 · 12y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of pimavanserin, including capsules containing the drug and processes for manufacturing them.

USPTO Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: US10646480
Jurisdiction: US
Classification: Formulation
Expires: 2038-08-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Acadia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.